Why Novo Nordisk's Big London Meeting Didn't Calm Investors
Novo Nordisk held its 2026 Capital Markets Day in London on 21 September 2026. Novo Nordisk
The meeting ran from 09:00 to 15:30 London time / 10:00 to 16:30 Central European time. Top bosses spoke about plans, drugs in testing, daily business and results. Novo Nordisk
The company said it would update its plans and its goals for 2030. Ritzau announcement
The date was known in advance. Its Q4 2025 investor slides mentioned a September 2026 Capital Markets Day, a planned meeting with investors. Novo Nordisk Q4 presentation
Shares tumbled in February after a trial setback for CagriSema, its next-generation obesity drug. Reuters
Shares fell 4.3% after a higher 2026 forecast (expected sales and profit) did not reassure investors worried about drugs in testing. The August fall followed that higher forecast, which left testing questions open. Reuters
By 27 March 2025, shares were down 25% in March alone, heading for the worst month since July 2002. Reuters Separately, shares fell as much as 20% after the company warned of 'unprecedented' price pressures.
On the environment, the firm aims for zero emissions from its own sites and transport by 2030. It aims for net zero across its full chain, including suppliers, by 2045. Both aims were in its Q2 2025 investor slides. Novo Nordisk Q2 presentation
The broader context here is trust. This matters if you save in a pension that owns big company shares. Normally a better forecast calms people. In August it did not. The price fell anyway. Fear about future drugs mattered more than good news for this year, like judging a farm on next year's crops rather than this year's harvest.
In my view, for forecasts, the London meeting tried to close that gap. Broad plans are not enough. Investors need detail. Which health uses are tested first. How tests are built. When patients join. How drugs will be sold. Updates on daily business show how today's sales pay for future tests. Goals for 2030 show how sales may become profit and where cash will go. Risk still sits with test results. The question is whether bosses gave enough detail to reduce doubt, or whether doubt stays in far-off years that count less today.
